Ozarelix

Ozarelix (D-63153) is a GnRH antagonist. Ozarelix induces cell apoptosis and arrests cell in G2/M phase. Ozarelix can be used in the research of prostate cancer[1].

Product Specifications

CAS Number

[295350-45-7]

Product Name Alternative

D-63153

UNSPSC

12352209

Hazard Statement

H302-H315-H319-H335

Target

Apoptosis; GnRH Receptor

Type

Peptides

Related Pathways

Apoptosis; GPCR/G Protein

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ozarelix.html

Solubility

10 mM in DMSO

Smiles

OC(C=C1)=CC=C1C[C@H](N(C)C([C@H](CO)NC([C@H](NC([C@H](NC([C@H](NC(C)=O)CC2=CC3=C(C=CC=C3)C=C2)=O)CC4=CC=C(C=C4)Cl)=O)CC5=CN=CC=C5)=O)=O)C(N[C@H](CCCCNC(N)=O)C(N[C@@H](CCCC)C(N[C@@H](CCCNC(N)=N)C(N6[C@@H](CCC6)C(N[C@H](C)C(N)=O)=O)=O)=O)=O)=O

Molecular Formula

C72H96ClN17O14

Molecular Weight

1459.09

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Festuccia C, et al. Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Prostate. 2010 Sep 1;70 (12) :1340-9.